A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Key Inclusion Criteria

- Diagnosis of advanced melanoma

- Prior treatment in a prespecified prior/parent ipilimumab study

- Men and women 18 years of age and older

First Reinduction:

- No unacceptable toxicity (except select reversible immune-related adverse events)
requiring ipilimumab discontinuation

- Had experienced documented progressive disease after expanded clinical benefit

Extended Maintenance

- Received ipilimumab at any dose in a parent study

- Achieved expanded clinical benefit at the time of entry to current study

Follow-up:

- Received ipilimumab at any dose in a closing parent study

- Deemed ineligible for reinduction or extended maintenance treatment or refused
treatment as reinduction or extended maintenance at the time of screening in the
current study, but consented to follow-up

Key Exclusion Criteria

- Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor
or agonist, other than ipilimumab

- Primary ocular or mucosal melanoma